
    
      This is a two centre, phase I clinical trial. A total of 18 patients will be studied using an
      open-label, dose escaling protocol; three patients will be entered into each of the five
      dosing panels. An additional three patients will be entered into the final dose panel to
      establish safety at the maximum tolerated dose.
    
  